Related Experiment Video
Updated: Feb 15, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Theranostics of Triple-Negative Breast Cancer Based on Conjugated Polymer Nanoparticles
Abstract:
Triple-negative breast cancer (TNBC) does not respond to many targeted drugs due to the lack of three receptors (i.e., estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2), which makes it difficult for TNBC detection and treatment. As compared to traditional breast cancer treatments such as surgery and chemotherapy, photodynamic therapy (PDT) has emerged as a promising approach for treating TNBC due to its precise controllability, high spatiotemporal accuracy, and minimal invasive nature. However, traditional photosensitizers used in PDT are associated with limitations of aggregation-caused quenching (ACQ), and the ACQ induced a significant decrease in reactive oxygen species (ROS) generation. To address these, we synthesized a cyclic arginine-glycine-aspartic acid (cRGD) peptide-decorated conjugated polymer (CP) nanoparticles with poly[2-methoxy-5-(2-ethyl-hexyloxy)-1,4-phenylenevinylene] (MEH-PPV) as the photosensitizer for the theranostics of TNBC. The synthesized CP nanoparticles show bright fluorescence with high stability and could effectively produce ROS under light irradiation. Cell viability studies showed that the CP nanoparticles have negligible dark cytotoxicity and could efficiently kill the αvβ3 integrin-overexpressed MDA-MB-231 cells (one subtype of TNBC cells) in a selective way. With the use of cRGD-modified MEH-PPV nanoparticles as the theranostic agent, it permits targeted imaging and PDT of TNBC both in the in vitro 3D tumor model and in living mice. The application of CP nanoparticles in the successful theranostics of TNBC could pave the way for future development of CP-based photosensitizers for clinical applications.
Insights
New conjugated polymer nanoparticles offer targeted photodynamic therapy (PDT) for triple-negative breast cancer (TNBC). These nanoparticles selectively kill cancer cells and enable imaging, overcoming limitations of traditional treatments.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Triple-negative breast cancer (TNBC) lacks targeted treatment options due to absent estrogen, progesterone, and HER2 receptors.
- Photodynamic therapy (PDT) shows promise for TNBC but is limited by photosensitizer aggregation-caused quenching (ACQ), reducing reactive oxygen species (ROS) generation.
- Traditional breast cancer treatments like surgery and chemotherapy have significant side effects and limitations.
Purpose of the Study:
- To develop novel conjugated polymer (CP) nanoparticles for targeted theranostics of TNBC.
- To overcome ACQ limitations in traditional photosensitizers for enhanced ROS production.
- To evaluate the efficacy of cRGD-peptide decorated CP nanoparticles for TNBC imaging and photodynamic therapy.
Main Methods:
- Synthesis of cyclic arginine-glycine-aspartic acid (cRGD) peptide-decorated conjugated polymer (CP) nanoparticles using poly[2-methoxy-5-(2-ethyl-hexyloxy)-1,4-phenylenevinylene] (MEH-PPV) as the photosensitizer.
- Characterization of CP nanoparticles for fluorescence, stability, and ROS generation under light irradiation.
- In vitro studies using MDA-MB-231 TNBC cells to assess cytotoxicity and selectivity.
- In vivo studies in mice and in vitro 3D tumor models to evaluate targeted imaging and PDT efficacy.
Main Results:
- Synthesized CP nanoparticles exhibited bright fluorescence, high stability, and efficient ROS generation upon light exposure.
- CP nanoparticles demonstrated negligible dark cytotoxicity and selective killing of αvβ3 integrin-overexpressed MDA-MB-231 TNBC cells.
- cRGD-modified MEH-PPV nanoparticles enabled targeted imaging and effective PDT of TNBC in both in vitro and in vivo models.
Conclusions:
- cRGD-decorated CP nanoparticles represent a promising theranostic agent for targeted TNBC treatment.
- This approach overcomes ACQ limitations, enhancing ROS generation for effective photodynamic therapy.
- The developed CP nanoparticles hold potential for future clinical applications in breast cancer theranostics.
Related Concept Videos
02:29Relative Strengths of Conjugate Acid-Base Pairs
02:34Polymers
02:34Polymers
02:50Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
02:50Conjugated Proteins
01:19Conjugation